Quantum-Si incorporated
NASDAQ:QSIBiotechnology
+$0.05 today
- Market cap
- $201.80M
- Beta
- 3.17
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$0.48
Volume 5.35M
Average 5.64M
QSI Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Quantum-Si incorporatedNASDAQ: QSI
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $14.49M rose 5.6% year over year, ahead of the -11.0% change in trailing-twelve-month research & development. Sequentially, it rose 32.3% from the prior quarter. Over 3 fiscal years it compounded at -9.3% a year.
Context
- Research & development amounted to 2206.9% of revenue in FY2025, up 256.5 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +5.6% holds above the trailing-twelve-month pace of -11.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 53.76M USD
- Year-over-year change
- -9.9%
- 4-year CAGR
- +3.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 53.76M | -9.9% |
| FY2024 | 2024-12-31 | 59.64M | -11.0% |
| FY2023 | 2023-12-31 | 67.03M | -7.0% |
| FY2022 | 2022-12-31 | 72.06M | +54.7% |
| FY2021 | 2021-12-31 | 46.58M | — |
Research & Development vs competitors
How QSI compares with its peers on the latest reported figures
- QSI's LTM Mar 2026 research & development of $54.53M is the 10th highest of the 11 companies compared; the peer median is $105.43M.
- Its year-over-year change of -11.0% is the 6th highest of 10, against a peer median of +17.5%.
- Research & development amounts to 2944.3% of revenue for QSI, versus a peer median of 121.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $172.31M | +17.5% | +18.0% | — | |
| LTM Mar 2026 | $155.55M | +43.4% | +21.4% | — | |
| LTM Mar 2026 | $137.53M | -14.3% | -5.0% | — | |
| LTM Mar 2026 | $124.71M | +42.2% | +15.6% | — | |
| LTM Mar 2026 | $112.11M | -27.3% | +3.1% | 121.1% | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $98.75M | +56.7% | +82.8% | — |
| LTM Mar 2026 | $94.95M | -15.8% | -17.7% | 119.9% | |
| LTM Mar 2026 | $94.92M | +19.3% | +28.8% | — | |
| LTM Mar 2026 | $66.77M | -12.8% | -2.0% | 185483.3% | |
| LTM Mar 2026 | $54.53M | -11.0% | -9.3% | 2944.3% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $28.47M | — | +131.7% | — |
| Peer median (excluding QSI) | $105.43M | +17.5% | +16.8% | 121.1% | |
Competitors are the stored peer set for QSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1.08M | 3.06M | 2.44M |
| Cost of Revenue | 0 | 0 | 594K | 1.46M | 1.28M |
| Gross Profit | 0 | 0 | 488K | 1.6M | 1.15M |
| Gross Margin | — | — | 45.1% | 52.3% | 47.3% |
| Research & Development | 46.58M | 72.06M | 67.03M | 59.64M | 53.76M |
| Selling, General & Admin | 50.33M | 42.3M | 44.63M | 50.54M | 44.75M |
| Operating Expenses | 96.91M | 123.84M | 111.66M | 110.18M | 98.51M |
| Depreciation & Amortization | 1.04M | 2.58M | 4.16M | 4.6M | 4.45M |
| EBITDA | (93.94M) | (111.77M) | (91.8M) | (96.35M) | (96.83M) |
| EBITDA Margin | — | — | -8484.7% | -3150.8% | -3974.8% |
| Operating Income | (96.91M) | (123.84M) | (111.17M) | (108.58M) | (97.36M) |
| Operating Margin | — | — | -10274.6% | -3550.6% | -3996.7% |
| Interest Income | 0 | 0 | 0 | 0 | 8.96M |
| Interest Expense | 5K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.92M | (8.6M) | 15.21M | 7.63M | (3.92M) |
| Income Before Tax | (94.99M) | (132.44M) | (95.96M) | (100.95M) | (101.28M) |
| Pre-Tax Margin | — | — | -8868.8% | -3301.2% | -4157.7% |
| Income Tax Expense | 0 | 0 | 0 | 56K | 58K |
| Net Income | (94.99M) | (132.44M) | (95.96M) | (101.01M) | (101.34M) |
| Net Margin | — | — | -8868.8% | -3303.0% | -4160.1% |
| EPS (Basic) | (1.19) | (0.95) | (0.68) | (0.71) | (0.51) |
| EPS (Diluted) | (1.19) | (0.95) | (0.68) | (0.71) | (0.51) |
| Weighted Avg Shares | 79.58M | 139.26M | 141.3M | 143.2M | 197.77M |
| Weighted Avg Shares (Diluted) | 79.58M | 139.26M | 141.3M | 143.2M | 197.77M |
Quantum-Si incorporated
NASDAQ:QSI
Intrinsic Alpha fair value
Locked
Current Price
$1.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.